Logo Logo
Help
Contact
Switch Language to German
Apfelbeck, Maria; Grimm, Tobias; Kretschmer, Alexander; Buchner, Alexander; Schneevoigt, Birte-Swantje; Jokisch, Friedrich; Grabbert, Markus; Schulz, Gerald; Stief, Christian G.; Karl, Alexander (2017): Follow-up of high-risk bladder cancer-Is it safe to perform fluorescence endoscopy multiple times in the same patient? In: Urologic Oncology-Seminars and Original investigations, Vol. 35, No. 10, 602.e19
Full text not available from 'Open Access LMU'.

Abstract

Purpose: As the use of fluorescence endoscopy is recommended today by different guidelines during the follow-up of high-grade non muscle-invasive bladder cancer, the aim of this study is to analyze whether the multiple use of hexylaminolevulinate (HAL) for TUR-BT can be performed safely within the same patient over a time interval. Methods: Data of patients diagnosed and treated with HAL-TUR-B at our institute between 2008 and 2013 were analyzed. Special interest was given to side effects observed during the instillation of the substance, on the whole day of the instillation and during the entire hospital stay. We focussed on side effects associated with the use of HAL, such as allergic reactions, urinary tract infections, photosensitization of the skin, and relevant changes in blood pressure. Results: In the time between 2008 and 2013, 2480 HAL-TUR-BTs were performed in total at our institute. In 80 patients, HAL-TUR-BT was used at least 2 times, and on average 4 times (2-12 times). Only patients with multiple uses were included for our final analysis. We observed no allergizations in any of the treated patients. Minor side effects were urinary tract infections (n = 4), dysuria (n = 4), pollakisuria (n = 9), and bladder spasms (n = 17). Conclusion: In our study cohort, the multiple use of HAL-TUR-BT within the same patient caused no major side effects or an induction of allergization against the substance. We, therefore, conclude that HAL-TUR-BT can be performed safely in the same patient during the follow-up of aggressive tumors as recommended by different guidelines today.